Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
1.
Pediatr Hematol Oncol ; 36(2): 103-112, 2019 Mar.
Article in English | MEDLINE | ID: mdl-30978130

ABSTRACT

Objectives: Diffusion-weighted magnetic resonance imaging (DW-MRI) offers potential to monitor response and predict survival in high-grade gliomas (HGG) and diffuse intrinsic pontine gliomas (DIPG). We hypothesized that post-radiotherapy DW-MRI may provide prognostic imaging biomarkers in children and young adults with these tumors. Methods: Patients aged ≤21 years diagnosed between 2005 and 2012 were eligible. The tumor median apparent diffusion coefficient (ADC) and its 5th percentile (C5-ADC) were determined at the first post-radiotherapy scan and at the time of radiological progression. DW-MRI parameters were correlated with survival endpoints, temozolomide use and pseudoprogression, when it occurred. Results: Out of 40 patients (20 HGG, 20 DIPG), 23 had evaluable DW-MRI post-radiotherapy and 25 at radiological progression. There were 6 episodes of pseudoprogression. Hazard ratios (95%CI) for progression-free survival were 0.998 (0.993-1.003) for median ADC and 1.003 (0.996-1.010) for C5-ADC. Hazard ratios (95%CI) for overall survival were 1.0009 (0.996-1.006) for median ADC and 0.998 (0.992-1.004) for C5-ADC. Post-radiotherapy median and C5-ADC values were not significantly different between patients treated with radiotherapy alone versus radiotherapy/temozolomide. The median and C5-ADC values were not significantly different at the time of pseudoprogression compared to those at tumor progression. Conclusions: Post-radiotherapy median ADC and C5-ADC were not prognostic, nor able to differentiate radiosensitization with temozolomide or occurrence of pseudoprogression in this cohort of HGG and DIPG patients. Further exploration of alternative DW parameters, study timepoints or data modeling may contribute to the development of prognostic/predictive imaging biomarkers for children and young adults with HGG or DIPG.


Subject(s)
Brain Neoplasms/radiotherapy , Diffusion Magnetic Resonance Imaging , Glioma/radiotherapy , White Matter/pathology , Adolescent , Antineoplastic Agents/therapeutic use , Brain Neoplasms/drug therapy , Brain Neoplasms/mortality , Brain Neoplasms/pathology , Brain Stem Neoplasms/drug therapy , Brain Stem Neoplasms/mortality , Brain Stem Neoplasms/pathology , Brain Stem Neoplasms/radiotherapy , Child , Child, Preschool , Combined Modality Therapy , Diffusion , Disease Progression , Female , Glioma/drug therapy , Glioma/mortality , Glioma/pathology , Humans , Male , Prognosis , Proportional Hazards Models , Temozolomide/therapeutic use , Young Adult
2.
J Neurooncol ; 129(1): 109-21, 2016 08.
Article in English | MEDLINE | ID: mdl-27180091

ABSTRACT

Pseudoprogression (PsP) is a treatment-related phenomenon which hinders response interpretation. Its prevalence and clinical impact have not been evaluated in children/adolescents. We assessed the characteristics, risk factors and prognosis of PsP in children/adolescents and young-adults diagnosed with non-brainstem high grade gliomas (HGG) and diffuse intrinsic pontine gliomas (DIPG). Patients aged 1-21 years diagnosed with HGG or DIPG between 1995 and 2012 who had completed radiotherapy were eligible. PsP was assessed according to study-specific criteria and correlated with first-line treatment, molecular biomarkers and survival. Ninety-one patients (47 HGG, 44 DIPG) were evaluable. Median age: 10 years (range, 2-20). Eleven episodes of PsP were observed in 10 patients (4 HGG, 6 DIPG). Rates of PsP: 8.5 % (HGG); 13.6 % (DIPG). Two episodes of PsP were based on clinical findings alone; nine episodes had concurrent radiological changes: increased size of lesions (n = 5), new focal enhancement (n = 4). Temozolomide, MGMT methylation or H3F3A mutations were not found to be associated with increased occurrence of PsP. For HGG, 1-year progression-free survival (PFS) was 41.9 % no-PsP versus 100 % PsP (p = 0.041); differences in 1-year overall survival (OS) were not significant. For DIPG, differences in 1-year PFS and OS were not statistically significant. Hazard ratio (95 %CI) of PsP for OS was 0.551 (0.168-1.803; p = 0.325) in HGG; and 0.308 (0.107-0.882; p = 0.028) in DIPG. PsP occurred in both pediatric HGG and DIPG patients at a comparable rate to adult HGG. PsP was associated with improved 1-yr PFS in HGG patients. PsP had a protective effect upon OS in DIPG patients.


Subject(s)
Brain Neoplasms/genetics , Brain Neoplasms/pathology , Brain Stem Neoplasms/genetics , Brain Stem Neoplasms/pathology , Disease Progression , Glioma/genetics , Glioma/pathology , Adolescent , Adult , Antineoplastic Agents, Alkylating/adverse effects , Child , Child, Preschool , Combined Modality Therapy/adverse effects , DNA Methylation , DNA Modification Methylases/metabolism , DNA Repair Enzymes/metabolism , Dacarbazine/adverse effects , Dacarbazine/analogs & derivatives , Disease-Free Survival , Female , Histones/genetics , Humans , Infant , Male , Radiotherapy/adverse effects , Risk Factors , Temozolomide , Treatment Outcome , Tumor Suppressor Proteins/metabolism , Young Adult
3.
Pediatr Blood Cancer ; 63(8): 1400-6, 2016 08.
Article in English | MEDLINE | ID: mdl-27149049

ABSTRACT

INTRODUCTION: RECIST guidelines constitute the reference for radiological response assessment in most paediatric trials of anticancer agents. However, these criteria have not been validated in children. We evaluated the outcomes and patterns of progression of children/adolescents enrolled in phase I trials in two paediatric drug development units. METHODS: Patients aged ≤21 assessed with RECIST (v1.0 or v1.1) were eligible. Clinico-radiological data were analysed using Mann-Whitney U and log-rank tests to correlate response categories and sum of longest diameters (SLD) with time-to-event variables and overall survival (OS). RESULTS: Sixty-one patients (71 enrolments) were evaluated; median age: 12.7 years (range, 3.1-20.9). Overall, 7% achieved complete/partial response (n = 5) and 31% disease stabilisation (n = 22). Median (95% CI) OS (in months) was 29.1 (27.6-30.6) with complete/partial response, 8.9 (2.0-15.8) with stable disease and 2.8 (2.3-3.3) with disease progression (P < 0.001); 32.6% patients with measurable disease presented exclusive progression of existing non-target lesions and/or new lesions. The change in SLD at best response showed a linear correlation with duration of response (r = -0.605; P = 0.004) and time on trial (r = -0.61; P = 0.003), but the change in SLD at progression did not correlate with time to progression (r = -0.219; P = 0.206). CONCLUSIONS: Response assessment according to RECIST correlated with OS in children/adolescents treated on phase I trials. The reduction in SLD at best response correlated with more prolonged responses. Tumour size did not constitute an optimal method to assess disease progression in one third of patients with measurable disease. Further refinement of current response assessment guidelines will enable the development of paediatric-specific radiological criteria.


Subject(s)
Antineoplastic Agents/therapeutic use , Disease Progression , Neoplasms/drug therapy , Neoplasms/radiotherapy , Response Evaluation Criteria in Solid Tumors , Adolescent , Adult , Child , Child, Preschool , Disease-Free Survival , Female , Humans , Male , Neoplasms/pathology , Treatment Outcome , Young Adult
4.
Pediatr Radiol ; 45(11): 1600-15, 2015 Oct.
Article in English | MEDLINE | ID: mdl-26045035

ABSTRACT

Cancer is the leading cause of death in children older than 1 year of age and new drugs are necessary to improve outcomes. Imaging is crucial to the drug development process and assessment of therapeutic response. In adults, tumours are often assessed with CT using size criteria. Unfortunately, techniques established in adults are not necessarily applicable in children due to differing pathophysiology, ability to cooperate and increased susceptibility to ionising radiation. MRI, in particular quantitative MRI, has to date not been fully utilised in children with extracranial neoplasms. The specific challenges of imaging in children, the potential for functional imaging techniques to inform upon and their inclusion in clinical trials are discussed.


Subject(s)
Clinical Trials as Topic/methods , Drug Monitoring/methods , Magnetic Resonance Imaging/methods , Neoplasms/diagnosis , Neoplasms/drug therapy , Tomography, X-Ray Computed/methods , Adolescent , Child , Child, Preschool , Drug Design , Female , Humans , Infant , Infant, Newborn , Male , Treatment Outcome
5.
Skeletal Radiol ; 40(11): 1427-34, 2011 Nov.
Article in English | MEDLINE | ID: mdl-21286713

ABSTRACT

PURPOSE: Acetabular morphology is an important predictor of the severity of osteoarthrosis and survival of hip prostheses but there is limited data on the normal range of acetabular measurements on plain radiographs. The aim of this project was to determine the statistically normal ranges of acetabular inclination (AI) and center-edge angle (CEA). METHOD: One hundred coronal CT localizers (50 men and 50 women aged 20-30 years) were included in this study. All the patients underwent CT examination for thoracic or intra-abdominal indications. Patients with pelvic disease, fractures, history of serious trauma, or previous pelvic surgery were excluded. One pair of independent observers measured the AI and pelvic tilt (PT), and a further pair measured the center-edge angle (CEA), using electronic calipers on a high-resolution PACS workstation. RESULTS: AI and CEA measurements were obtained for 200 hips. There was very good intra-class correlation between the observers (r = 0.7-0.8). The mean AI was 38.8° (2SD 32.1-45.5°). That in men was 38.0° (2 SD 31.8-44.1°) and 39.6° (2 SD 32.7-46.8°) in women, which was statistically significantly different (p < 0.001). The mean CEA measurement for all patients was 36.3° (SD 13.8°), for men 37.7° (SD 10.8°) and for women 34.9° (SD 11.4°) with a statistically significant gender difference (p < 0.001). The mean pelvic tilt measurement (sacro-coccygeal-pubic symphysis) was 38.3 mm (2 SD 18.3-58.3 mm) with a significant gender difference (p < 0.001). CONCLUSIONS: The results of this study define reference ranges of two common measures of acetabular morphology and confirm statistically significant differences between men and women.


Subject(s)
Acetabulum/diagnostic imaging , Hip Joint/diagnostic imaging , Tomography, X-Ray Computed , Acetabulum/anatomy & histology , Adult , Female , Hip Joint/anatomy & histology , Humans , Male , Reference Values , Young Adult
6.
Knee ; 17(1): 1-6, 2010 Jan.
Article in English | MEDLINE | ID: mdl-19608420

ABSTRACT

Magnetic resonance (MR) imaging is a frequently performed investigation for disease of the knee. Bone marrow oedema (BME) is a common MR finding with a number of causes including trauma, tumour, infection, inflammatory arthropathies and BME syndromes. This article illustrates the range of MR appearances of BME around the knee and describes secondary signs that allow the reader to determine the cause of disease and to distinguish BME from normal marrow signal changes.


Subject(s)
Bone Marrow Diseases/pathology , Edema/diagnosis , Knee Joint/pathology , Magnetic Resonance Imaging/methods , Edema/etiology , Humans
SELECTION OF CITATIONS
SEARCH DETAIL